Save
INTRATHECAL MORPHINE INFUSION THERAPY IN MANAGEMENT OF CHRONIC NON-CANCER PAIN: AFTER JULY 2014 IN KOREA.
Author(s): ,
Choi, J.K.*
Affiliations:
Seoul National University Hospital, Anesthesiology and Pain medicine, Seoul, Republic of Korea
,
Kim, E.
Affiliations:
Seoul National University Hospital, Anesthesiology and Pain medicine, Seoul, Republic of Korea
,
Moon, J.Y.
Affiliations:
Seoul National University Hospital, Anesthesiology and Pain medicine, Seoul, Republic of Korea
Kim, Y.C.
Affiliations:
Seoul National University Hospital, Anesthesiology and Pain medicine, Seoul, Republic of Korea
ESRA Academy. Kim E. Sep 13, 2017; 190773; 279 Topic: PAIN THERAPY (ACUTE - CHRONIC)
Dr. Eunkyoung Kim
Dr. Eunkyoung Kim

Access to Premium content is currently a membership benefit.


Click here to join ESRA or renew your membership.

Abstract
Discussion Forum (0)
Rate & Comment (0)
Background and Aims:

Intrathecal drug pump is an effective modality in managing chronic non-cancer pain and Korean new reimbursement about intrathecal drug pump in July 2014 has been announced. We analyzed what has been changed in chronic non-malignant pain management after the new policy.

Methods:

A retrospective chart review of 23 patients who underwent intrathecal morphine pump (ITMP) implantation in the period of July 2014 and May 2016 was performed. Changes in morphine dose, numeric rating scale (NRS) scores, patients’ overall satisfaction and financial break-even point were investigated.

Results:

Nineteen patients were included in this investigation and all patients showed adequate NRS score reduction after ITMP implantation. There was no fetal complication with relatively low intrathecal morphine dose. Most patients showed opioid dose escalation and 63% patients needed adjuvant medication after ITMP implantation. 63% of patients satisfied with ITMP treatment and the financial break-even point met at 36.8~52.6 months.

Conclusions:

The patients in this investigation achieved effective chronic non-malignant pain management with less systemic side-effect and reasonable cost-effectiveness in long-term use with intrathecal morphine pump therapy. New reimbursement policy has contributed to lower the economic barrier of ITMP from chronic pain patients and improved quality of chronic non-cancer pain patients’ life.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings